Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7389447 | Value in Health | 2017 | 7 Pages |
Abstract
This study confirms that the quality of scientific evidence used in HTA of high-risk MDs is low and therefore the use of evidence needs improvement. The European Commission recently updated the regulation on MDs but mainly focused on the safety of materials and the CE (Conformité Européene [European Conformity]) mark. Our results show that additional changes are necessary, specifically with regard to the marketing authorization process of MDs, with stricter quality requirements based on methodologically robust trials, possibly in combination with other evidence sources.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Britta MScPH, Sabine MScPH, Dimitra DrPH, Matthias MD, PhD, Reinhard Prof. Dr. med.,